Reducing the Risk of Stroke
Yoshikazu Takahashi, of Nigata, Japan, was diagnosed with non valvular atrial fibrillation (NVAF) when he was 60 years old.
“I never imagined that nonvalvular atrial fibrillation could lead to something more serious. I was relieved when my doctor explained more about the disease and how Eliquis could reduce my risk of having a stroke,” Yoshikazu said.
Yoshikazu retired from his position at a paper trading company and is back to work as a sales assistant at a printing company, accompanying sales representatives when they meet with clients. Today, six years since his diagnosis, his is grateful that his doctor prescribed Eliquis for him.
“After I learned more about the possible risks of stroke associated with NVAF, the fact that I have not suffer a stroke holds special meaning to me,” he said.
Eliquis remains the number one oral anticoagulant globally; it is used to reduce the risk of stroke and blood clots in people who have nonvalular atrial fibrillation; to treat blood clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism), and to reduce the risk of them occurring again, and to reduce the risk of the formation of a blood clot in the legs and lungs in people who have had hip or knee replacement surgery.